Eli Casdin, Chief Investment Officer and Founder, founded Casdin Capital in 2011. For the last 16 years he has analyzed and invested in disruptive technologies and business models in life sciences and healthcare.
Prior to founding Casdin Capital, Eli was a vice president at Alliance Bernstein “thematic” based investment group where he researched and invested in the implications of new technologies for the life science and healthcare sectors. His Alliance Bernstein black book, “The Dawn of Molecular Medicine” detailed the early yet already accelerating wave of innovations in life sciences, and the next wave of investment opportunities. Eli’s prior experience includes time at Bear Stearns and Cooper Hill Partners, a healthcare focused investment firm.
Eli earned a B.S. from Columbia University and an MBA from Columbia Business School.
Casdin Capital
1 followers
Casdin Capital, LLC (“Casdin”) is a New York-based fundamental research investment firm focused on the life sciences and healthcare industry. The firm manages a long short equity fund and makes investments in early stage to late stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets under management. Casdin started from a position of curiosity, honesty, and passion to gain a deep and thoughtful understanding of opportunities in the life science ecosystem. They commit to finding the highest quality management teams doing the work to create high growth companies. They use data to continually advance their knowledge and we are long term investors. They believe in collaboration and transparency and operate at the forefront of innovation.